Every 10-Q that Alaunos Therapeutics, Inc. (TCRT) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow TCRT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full TCRT filings page.
Alaunos Therapeutics, Inc. reports that it remains a preclinical-stage obesity and metabolic disorders company with no product revenue and continued losses. For the six months ended June 30, 2026, it recorded a net loss of $1.96 million and had an accumulated deficit of $926.6 million since inception. Cash and cash equivalents were only $0.12 million, with total assets of $1.52 million and stockholders’ equity of $0.65 million, resulting in a working capital deficit.
Management states that current capital will fund operations only into the third quarter of 2026 and concludes there is substantial doubt about the company’s ability to continue as a going concern without substantial additional financing. The company has an equity purchase agreement that yielded just $70,000 of net proceeds in the first half of 2026 and has no committed additional capital. Alaunos also received a Nasdaq stockholders’ equity deficiency notice, as equity is below the $2.5 million continued listing requirement, and it highlights possible future exposure to a proposed $5.0 million Market Value of Listed Securities standard.
Operationally, Alaunos is winding down legacy TCR-T programs and focusing on lead small-molecule candidate ALN1003 for obesity and metabolic syndrome, reporting encouraging non-GLP diet-induced obesity mouse data across weight loss, liver markers, and insulin-resistance-related biomarkers. However, these findings are preclinical, non-GLP, and subject to substantial development and financing risks before any clinical testing.
Alaunos Therapeutics, Inc. reported a Q1 2026 net loss of $1.0 million with no product revenue and total assets of $1.9 million. Cash and cash equivalents were just $0.35 million, and management expects this to fund operations only into the second quarter of 2026.
Stockholders’ equity was $1.29 million, below Nasdaq’s $2.5 million minimum equity requirement, and the company has received a related Nasdaq deficiency notice. Accumulated deficit reached approximately $925.6 million as the company continues to invest in its preclinical oral obesity and metabolic disorders program, including lead compound ALN1003, which has shown encouraging diet-induced obesity mouse data.
The company discloses substantial doubt about its ability to continue as a going concern without raising additional capital and notes a material weakness in internal control over financial reporting, while also highlighting limited royalty income and continued cost reductions in general and administrative expenses.
Alaunos Therapeutics (TCRT) filed its Q3 2025 10‑Q, highlighting continued cost control alongside funding actions to support its shift to an oral small‑molecule obesity program. The company posted a net loss of $1,159 thousand for the quarter, with operating expenses of $1,187 thousand. Cash and cash equivalents were $1,938 thousand, and stockholders’ equity was $2,803 thousand as of September 30, 2025.
Alaunos raised capital during 2025 via a registered direct offering of common stock and pre‑funded warrants, and private placements of Series A‑1 and Series A‑2 preferred stock. It also entered an equity purchase agreement permitting sales of up to $25.0 million of common stock over 24 months, and issued a five‑year warrant at $4.00 per share in connection with that agreement. The company reports cash runway into the first quarter of 2026 and discloses substantial doubt about its ability to continue as a going concern absent additional financing.
The strategic focus remains on preclinical obesity candidates, with in vitro and in vivo work underway. Alaunos regained compliance with Nasdaq continued listing requirements in August 2025. Common shares outstanding were 2,205,846 as of September 30, 2025.